BioGaia (BIOG): Strategic Shift to Direct Sales May Obscure Long-Term Upside - Idea Note
BioGaia’s transition from distributor-led to direct sales has temporarily compressed margins and slowed growth, leaving the share price flat despite strong fundamentals. The company’s balance sheet and profitability remain robust, with an EBIT margin near 30% and accelerating growth in the Adult segment. Insider buying and leadership changes signal confidence, but at 23.7x EV/EBIT, the valuation still prices in much of the quality. We’re adding BioGaia to the watchlist to track further strategic execution and potential market overreaction.
Talkpool has reshaped itself into a lean, cash-generative network services firm following the IoT divestment. With steady organic growth and improving margins, current earnings already cover most of its enterprise value. Modest growth and normalization could drive the EV/EBIT below 4x by 2028, suggesting attractive valuation potential.
Byggmästaren (AJAB): Safe Life Divestment Unlocks Value While Maintaining Strategic Exposure
Kavaljer believes that Byggmästaren’s partial divestment of Safe Life to Bridgepoint for SEK 525 million represents a significant valuation validation.
Kavaljer finds that Bahnhof, despite being a historically fantastic contributor to fund returns, now faces significant headwinds that justify exiting the position.
Arjo is a Swedish medical technology company that provides products and solutions to improve mobility and care for people with reduced mobility and age-related conditions.
